Posted by Michael Wonder on 10 Aug 2021
Implementing outcomes based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel
10 August 2021 - Enthusiasm for the use of outcomes based managed entry agreements to manage uncertainties apparent at the time of appraisal/pricing and reimbursement of new medicines has waned over the past decade, as challenges in establishment, implementation and re-appraisal have been identified.
With the recent advent of innovative treatments for rare diseases that have uncertainties in the clinical evidence base, but which could meet a high unmet need, there has been renewed interest in the potential of outcomes based managed entry agreements.
